Regentis reports surgeon interest in GelrinC at ICRS Summit in Portugal
The Israeli regenerative medicine company said European clinical sites for its CE Mark-approved cartilage implant are also feeding into an ongoing U.S. FDA pivotal trial.
SEC filing